DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

Main Inclusion Criteria: * Male and female patients between 10 and 18 years of age * Insulin dependent Type 1 Diabetes mellitus diagnosed within the previous 4 months at time of screening * Fasting C-peptide level at time of screening above or equal to 0.12 nmol/L * Elevated GAD65 antibodies (GADA) at time of screening Main Exclusion Criteria: * Treatment with immunosuppressants, continuous anti-inflammatory drug, Vitamin D or any anti-diabetic medications other than insulin * A history of certain diseases or conditions (e.g. anemia, HIV, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc) * Treatment with any vaccine within 4 months prior to first planned administration of GAD-Alum/placebo or planned treatment with vaccine up to 4 months after the last injections with GAD-Alum/Placebo, including influenza vaccines * Participation in other clinical trials with a new chemical entity within the previous 3 months * Pregnancy or planned pregnancy within 1 year after the last GAD-Alum/placebo dose * Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study